Ahmed A. J. Mahmood
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ahmed A. J. Mahmood has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed H. Saleh
Geology Department, Faculty of Science, Zagazig University, Zagazig, Egypt
1 shared publication - Asma Rashid
Department of Psychology, University of Campania, Luigi Vanvitelli, Caserta, Italy
1 shared publication Douglas Whatmore
Department of Medicine, Eastern Idaho Regional Medical Center, Idaho Falls, Idaho, USA
1 shared publication- Freya Scutt
Plastic Surgery, Aberdeen Royal Infirmary, Aberdeen, GBR
1 shared publication - Jennifer Greenhowe
Plastic and Reconstructive Surgery, Royal Aberdeen Children’s Hospital, Aberdeen, GBR
1 shared publication - Mahmood H. M. Jasim
Department of Pharmaceutical Chemistry College of Pharmacy University of Mosul Mosul Iraq
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Higher Institute of Medical Sciences and Technologies, Bani Walid in Libyan Journal of Applied and Contemporary Sciences
- Vol. 1 (2) , 12-25
Benzimidazole: A Promising Scaffold as Multitargeted Anticancer Agents - A Review of Chemistry and Mechanisms and Therapeutic Prospects
Cancer is still one of the biggest challenges facing global public health, and accounts for the second largest number of deaths globally. The design, discovery, and development of active anticancer agents including antitumor, antiproliferative, and antineoplastic agents therefore has been an important goal of current drug research. A longstanding hurdle in traditional cytotoxic treatment regimens is the poor selectivity for cancer cells, leading to harmful side effects in normal tissues. Given purine's significance in biology, there has been a tremendous amount of research on the substitution of the purine nucleoside scaffold with various bioisosteres, such as benzimidazole, which is considered a bioisostere of the purine nucleoside scaffold, is a privileged pharmacophore in medicinal chemistry due to its wide range of biological activities such as antiulcer, antioxidant, anti-HIV reverse transcriptase (HIV-RT) inhibitor, anticancer, anthelmintic, antimicrobial, and antihistaminic. The benzimidazole scaffold has been widely explored as a template in the development of drugs for cancer and antineoplastic therapeutics. Various transformations at different positions of the benzimidazole core have been obtained leading to the development of a wide range of active compounds exhibiting potent antiproliferative activities. This review provides an inclusive overview of the medicinal chemistry of substituted benzimidazole derivatives with special emphasis on their SAR explanations that influence their cytotoxic activity against diverse human tumor cell lines. Major mechanistic targets investigated include cyclin dependent kinase (CDK) inhibition, DNA topoisomerase inhibition, poly (ADP-ribose) polymerase (PARP) inhibition, dihydrofolate reductase (DHFR) inhibition, protein tyrosine kinase (PTK) inhibition, and microtubule disruption. The discussion also focuses on benzimidazole-based anticancer agents that have been clinically approved as well as potential investigational leads, demonstrating the sustained importance of this scaffold in oncology drug discovery
- 1 January 2026
- Published by Higher Institute of Medical Sciences and Technologies, Bani Walid in Libyan Journal of Applied and Contemporary Sciences
- Vol. 1 (2) , 12-25
Open AccessBenzimidazole: A Promising Scaffold as Multitargeted Anticancer Agents - A Review of Chemistry and Mechanisms and Therapeutic Prospects
Cancer is still one of the biggest challenges facing global public health, and accounts for the second largest number of deaths globally. The design, discovery, and development of active anticancer agents including antitumor, antiproliferative, and antineoplastic agents therefore has been an important goal of current drug research. A longstanding hurdle in traditional cytotoxic treatment regimens is the poor selectivity for cancer cells, leading to harmful side effects in normal tissues. Given purine's significance in biology, there has been a tremendous amount of research on the substitution of the purine nucleoside scaffold with various bioisosteres, such as benzimidazole, which is considered a bioisostere of the purine nucleoside scaffold, is a privileged pharmacophore in medicinal chemistry due to its wide range of biological activities such as antiulcer, antioxidant, anti-HIV reverse transcriptase (HIV-RT) inhibitor, anticancer, anthelmintic, antimicrobial, and antihistaminic. The benzimidazole scaffold has been widely explored as a template in the development of drugs for cancer and antineoplastic therapeutics. Various transformations at different positions of the benzimidazole core have been obtained leading to the development of a wide range of active compounds exhibiting potent antiproliferative activities. This review provides an inclusive overview of the medicinal chemistry of substituted benzimidazole derivatives with special emphasis on their SAR explanations that influence their cytotoxic activity against diverse human tumor cell lines. Major mechanistic targets investigated include cyclin dependent kinase (CDK) inhibition, DNA topoisomerase inhibition, poly (ADP-ribose) polymerase (PARP) inhibition, dihydrofolate reductase (DHFR) inhibition, protein tyrosine kinase (PTK) inhibition, and microtubule disruption. The discussion also focuses on benzimidazole-based anticancer agents that have been clinically approved as well as potential investigational leads, demonstrating the sustained importance of this scaffold in oncology drug discovery
- 28 September 2023
- Published by Indian Drug Manufacturers' Association (IDMA) in INDIAN DRUGS
- Vol. 60 (09) , 37-48
IN SILICO STUDY OF NEW SCHIFF BASE-AND AMIDE-BORONIC ACID DERIVATIVES AS POTENTIAL INHIBITORS OF Β-LACTAMASES
Bacteria are becoming more and more resistant to β-lactam antibiotics. One approach to lower such resistance involves combining inhibitors of β-lactamase with β-lactams antibiotics. As such, the need for innovative inhibitors of β-lactamases is urgent. therefore, the aim of this research was to design and dock two new series of amides and Schiff bases of the cyclic and noncyclic boronate derivatives into four subtypes from two different classes of the β-lactamase enzymes. In silico prediction of the pharmacokinetic profile of the designed compounds was also performed. the results revealed possible enhanced activity of 15 out of the 82 compounds, when matched with 4 existing β-lactamase inhibitors (clavulanic acid, sulbactam, tazobactam and vaborbactam). the 15 compounds showed favorable docking interactions with the residues in the active site of all enzymes. the predicted pharmacokinetic characteristics also showed that the 15 compounds are promising as oral agents. the designed compounds have the potential to act as inhibitors of β-lactamase as shown by their docking results on 4 β-lactamase crystal structures. the pharmacokinetic profile of 15 compounds is also promising, making them suitable candidates for synthesis and in vitro testing.
- 28 September 2023
- Published by Indian Drug Manufacturers' Association (IDMA) in INDIAN DRUGS
- Vol. 60 (09) , 37-48
IN SILICO STUDY OF NEW SCHIFF BASE-AND AMIDE-BORONIC ACID DERIVATIVES AS POTENTIAL INHIBITORS OF Β-LACTAMASES
Bacteria are becoming more and more resistant to β-lactam antibiotics. One approach to lower such resistance involves combining inhibitors of β-lactamase with β-lactams antibiotics. As such, the need for innovative inhibitors of β-lactamases is urgent. therefore, the aim of this research was to design and dock two new series of amides and Schiff bases of the cyclic and noncyclic boronate derivatives into four subtypes from two different classes of the β-lactamase enzymes. In silico prediction of the pharmacokinetic profile of the designed compounds was also performed. the results revealed possible enhanced activity of 15 out of the 82 compounds, when matched with 4 existing β-lactamase inhibitors (clavulanic acid, sulbactam, tazobactam and vaborbactam). the 15 compounds showed favorable docking interactions with the residues in the active site of all enzymes. the predicted pharmacokinetic characteristics also showed that the 15 compounds are promising as oral agents. the designed compounds have the potential to act as inhibitors of β-lactamase as shown by their docking results on 4 β-lactamase crystal structures. the pharmacokinetic profile of 15 compounds is also promising, making them suitable candidates for synthesis and in vitro testing.
- Open Access
- 1 January 2023
- Published by Science Archives in Science Archives
- Vol. 04 (03) , 199-207
Novel β-lactamase inhibitors and the pursuit of MBL inhibitors to combat antibiotic-resistant bacteria: a review
Bacterial resistance is spreading internationally and poses a serious threat to humans. β-lactam resistance has enhanced to an uncontrolled rate due to many reasons. The most significant form of resistance is destruction of the ß-lactam ring by a bacterial enzyme named ß-lactamase enzyme which is essential for antibacterial activity. There are currently six β-lactamases inhibitors that can be used clinically in conjugation with the antibiotic in order to protect them from enzymatic attacks. They bind the β-lactamase enzyme thus the β-lactam antibiotic catches the transpeptidase (PBP) which has the responsibility of peptidoglycan synthesis and disables it thus causing cell wall lysis. However, in order to tackle the fast escalating ß-lactam resistance, additional research is needed in order to create novel drugs with broad-spectrum. Herein we represent the recently published works of the β-lactamases inhibitors. Until nowadays there are no clinically approved MBL inhibitors, Efforts should be put to discover and evaluate novel MBLi to impede the spread of pathogenic-resistant bacteria and minimize their global health impact. The scientists realize this fact and emphasize their effort toward MBL inhibitors.
- 1 January 2023
- Published by Science Archives in Science Archives
- Vol. 04 (03) , 199-207
Open AccessNovel β-lactamase inhibitors and the pursuit of MBL inhibitors to combat antibiotic-resistant bacteria: a review
Bacterial resistance is spreading internationally and poses a serious threat to humans. β-lactam resistance has enhanced to an uncontrolled rate due to many reasons. The most significant form of resistance is destruction of the ß-lactam ring by a bacterial enzyme named ß-lactamase enzyme which is essential for antibacterial activity. There are currently six β-lactamases inhibitors that can be used clinically in conjugation with the antibiotic in order to protect them from enzymatic attacks. They bind the β-lactamase enzyme thus the β-lactam antibiotic catches the transpeptidase (PBP) which has the responsibility of peptidoglycan synthesis and disables it thus causing cell wall lysis. However, in order to tackle the fast escalating ß-lactam resistance, additional research is needed in order to create novel drugs with broad-spectrum. Herein we represent the recently published works of the β-lactamases inhibitors. Until nowadays there are no clinically approved MBL inhibitors, Efforts should be put to discover and evaluate novel MBLi to impede the spread of pathogenic-resistant bacteria and minimize their global health impact. The scientists realize this fact and emphasize their effort toward MBL inhibitors.
- Open Access
- 23 November 2021
- Published by Springer Nature in Cureus
- Vol. 13 (11)
Bilateral Anteverted Conchal Bowls: Surgical Correction of a Rare Anomaly
Anteverted conchal bowl is a rare auricular anomaly in which a convexity of the conchal bowl is seen. The condition may pose both aesthetic and functional implications for affected patients. Most cases are benign and require minimal or no intervention. In severe cases, the external acoustic meatus can be occluded, giving rise to a host of complications. Correction of anteverted conchal bowls is achieved by either conservative or surgical modalities, with the latter commonly undertaken in the post-neonatal stage. Reconstructive surgery can be performed using relatively simple techniques and yields desirable results. Here, we present a case of a patient surgically treated in our Plastic Surgery Unit in the North East of Scotland, along with a description of the operative methods utilised.
- 23 November 2021
- Published by Springer Nature in Cureus
- Vol. 13 (11)
Open AccessBilateral Anteverted Conchal Bowls: Surgical Correction of a Rare Anomaly
Anteverted conchal bowl is a rare auricular anomaly in which a convexity of the conchal bowl is seen. The condition may pose both aesthetic and functional implications for affected patients. Most cases are benign and require minimal or no intervention. In severe cases, the external acoustic meatus can be occluded, giving rise to a host of complications. Correction of anteverted conchal bowls is achieved by either conservative or surgical modalities, with the latter commonly undertaken in the post-neonatal stage. Reconstructive surgery can be performed using relatively simple techniques and yields desirable results. Here, we present a case of a patient surgically treated in our Plastic Surgery Unit in the North East of Scotland, along with a description of the operative methods utilised.
- 1 January 2020
- Published by Medknow in International Journal of Academic Medicine
- Vol. 6 (1) , 36-39
Is emphysematous pyelitis a precursor lesion of emphysematous pyelonephritis? A case report of bilateral emphysematous pyelitis caused by extended-spectrum beta-lactamase Escherichia coli and literature review
The presence of air in different parts of renal excretory system needs accurate assessment, and careful consideration as its progression to renal parenchyma can lead to fulminant course with substantial mortality. Bilateral emphysematous pyelonephritis is a well-known entity, but bilateral emphysematous pyelitis (EP) along with emphysematous cystitis is extremely rare. An internet search with the term “bilateral emphysematous pyelitis” and “bilateral emphysematous pyelitis and ureteritis with cystitis” only found three case reports in English. We present an interesting case of bilateral EP, ureteritis, and cystitis in a nondiabetic male patient without any history of immunodeficiency (HIV or chronic steroid use) but with a history of nonobstructing bilateral multiple renal calculi who was successfully managed medically. EP, if diagnosed early and managed properly, has an excellent prognosis with complete recovery following medical treatment. The following core competencies are addressed in this article: Practice-Based Learning and Improvement, Patient care and Procedural skills, Medical Knowledge.
- 1 January 2020
- Published by Medknow in International Journal of Academic Medicine
- Vol. 6 (1) , 36-39
Is emphysematous pyelitis a precursor lesion of emphysematous pyelonephritis? A case report of bilateral emphysematous pyelitis caused by extended-spectrum beta-lactamase Escherichia coli and literature review
The presence of air in different parts of renal excretory system needs accurate assessment, and careful consideration as its progression to renal parenchyma can lead to fulminant course with substantial mortality. Bilateral emphysematous pyelonephritis is a well-known entity, but bilateral emphysematous pyelitis (EP) along with emphysematous cystitis is extremely rare. An internet search with the term “bilateral emphysematous pyelitis” and “bilateral emphysematous pyelitis and ureteritis with cystitis” only found three case reports in English. We present an interesting case of bilateral EP, ureteritis, and cystitis in a nondiabetic male patient without any history of immunodeficiency (HIV or chronic steroid use) but with a history of nonobstructing bilateral multiple renal calculi who was successfully managed medically. EP, if diagnosed early and managed properly, has an excellent prognosis with complete recovery following medical treatment. The following core competencies are addressed in this article: Practice-Based Learning and Improvement, Patient care and Procedural skills, Medical Knowledge.